Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27780914 | 0.87 | SMARCA2 (0.41) | AKR1C3AKR1C2RECQL | |
| SCHEMBL7962904 | 0.81 | PTGS1 (0.50) | AKR1C3AKR1C2PTGS1CHRM1PTGS2 | |
| SCHEMBL29272210 | 0.81 | PTGS1 (0.47) | PTGS1PTGS2HPGDPSEN1PSEN2 | |
| SCHEMBL23972495 | 0.80 | LMNA (0.45) | AKR1C3AKR1C2RECQLLMNAMAPK1 | |
| SCHEMBL13332664 | 0.79 | GPR119 (0.44) | AKR1C3AKR1C2MAPTSMN1; SMN2RECQL | |
| SCHEMBL1979197 | 0.79 | GPR119 (0.44) | AKR1C3AKR1C2MAPTSMN1; SMN2RECQL | |
| SCHEMBL24031007 | 0.79 | PTGS2 (0.46) | AKR1C3AKR1C2PTGS1PTGS2MAPT | |
| SCHEMBL14943113 | 0.79 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS1APPPTGS2 | |
| Hydrochloric Acid SCHEMBL6945545 | 0.77 | GABRP (0.49) | AKR1C3AKR1C2PTGS1PTGS2MAPT | |
| SCHEMBL4330263 | 0.77 | RECQL (0.44) | AKR1C3AKR1C2RECQLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | AKR1C3 3238/4885AKR1C2 3025/4885PTGS1 165/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | AKR1C3 4490/4885AKR1C2 4506/4885PTGS1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.